Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis.


Journal

Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895

Informations de publication

Date de publication:
06 2021
Historique:
received: 24 03 2020
accepted: 06 08 2020
revised: 28 07 2020
pubmed: 2 9 2020
medline: 17 8 2021
entrez: 2 9 2020
Statut: ppublish

Résumé

Data on the efficacy and safety of interferon (IFN)-α for the treatment of essential thrombocythemia (ET) and polycythemia vera (PV) are inconsistent. We conducted a systematic review and meta-analysis and searched MEDLINE and EMBASE via Ovid, Scopus, COCHRANE registry of clinical trials, and Web of Science from inception through 03/2019 for studies of pegylated IFN (peg-IFN) and non-pegylated IFN (non-peg-IFN) in PV and ET patients. Random-effects models were used to pool response rates for the primary outcome of overall response rate (ORR) defined as a composite of complete response, partial response, complete hematologic response (CHR) and partial hematologic response. Peg-IFN and non-peg-IFN were compared by meta-regression analyses. In total, 44 studies with 1359 patients (730 ET, 629 PV) were included. ORR were 80.6% (95% confidence interval: 76.6-84.1%, CHR: 59.0% [51.5%-66.1%]) and 76.7% (67.4-84.0%; CHR: 48.5% [37.8-59.4%]) for ET and PV patients, respectively. In meta-regression analyses results did not differ significantly for non-peg-IFN vs. peg-IFN. Annualized rates of thromboembolic complications and treatment discontinuation due to adverse events were low at 1.2% and 8.8% for ET and 0.5% and 6.5% for PV patients, respectively. Both peg-IFN and non-peg-IFN can be effective and safe long-term treatments for ET and PV.

Identifiants

pubmed: 32868875
doi: 10.1038/s41375-020-01020-4
pii: 10.1038/s41375-020-01020-4
pmc: PMC7917159
mid: NIHMS1618942
doi:

Substances chimiques

Antiviral Agents 0
Interferon-alpha 0

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1643-1660

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016359
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Références

Lancet Haematol. 2017 Apr;4(4):e165-e175
pubmed: 28291640
Leukemia. 2018 May;32(5):1057-1069
pubmed: 29515238
Blood. 2019 Oct 31;134(18):1498-1509
pubmed: 31515250
Blood. 2011 May 5;117(18):4706-15
pubmed: 21389325
Eur J Haematol. 1999 Jan;62(1):27-31
pubmed: 9918308
Eur J Cancer. 1991;27 Suppl 4:S69-71
pubmed: 1799484
Leuk Lymphoma. 1999 Dec;36(1-2):123-8
pubmed: 10613456
Leukemia. 2019 Dec;33(12):2974-2978
pubmed: 31363161
Blood. 2013 Aug 8;122(6):893-901
pubmed: 23782935
Curr Hematol Malig Rep. 2019 Aug;14(4):310-327
pubmed: 31228096
Semin Hematol. 1986 Jul;23(3):177-82
pubmed: 3749928
Am J Med Sci. 1998 Apr;315(4):237-41
pubmed: 9537637
Haematologica. 1991 Jan-Feb;76(1):75-7
pubmed: 2055565
Eur J Cancer. 1991;27 Suppl 4:S58-62; discussion S62-3
pubmed: 1799482
Cancer Chemother Pharmacol. 2003 Jan;51(1):81-6
pubmed: 12497210
Leukemia. 1992;6 Suppl 3:138S-140S
pubmed: 1602810
Haematologica. 2016 May;101(5):e182-4
pubmed: 26819057
Asian Pac J Cancer Prev. 2014;15(4):1681-4
pubmed: 24641389
Haematologica. 2020 Jan;105(1):102-111
pubmed: 31004015
Blood. 2015 Jul 23;126(4):560-1
pubmed: 26206947
J Epidemiol Community Health. 1998 Jun;52(6):377-84
pubmed: 9764259
Mayo Clin Proc. 2019 Apr;94(4):599-610
pubmed: 30824279
J Clin Oncol. 2011 Aug 10;29(23):3179-84
pubmed: 21747083
Eur J Haematol. 2018 Jul 30;:
pubmed: 30058088
Acta Haematol. 1994;91(3):126-9
pubmed: 8091933
Eur J Haematol. 2018 May;100(5):419-425
pubmed: 29369421
Blood. 2015 Oct 8;126(15):1762-9
pubmed: 26261238
Blood. 2013 Mar 7;121(10):1720-8
pubmed: 23315161
Eur J Cancer. 1991;27 Suppl 4:S72-4
pubmed: 1799486
Leuk Lymphoma. 2016 Feb;57(2):348-354
pubmed: 25956046
Blood. 2017 Dec 7;130(23):2475-2483
pubmed: 29212804
J Hematol Oncol. 2017 Jan 13;10(1):15
pubmed: 28086927
Haematologica. 2010 Aug;95(8):1435-8
pubmed: 20418246
Ann Hematol. 2018 Apr;97(4):617-627
pubmed: 29396713
Blood. 2012 Dec 20;120(26):5128-33; quiz 5252
pubmed: 23033268
Blood. 2008 Oct 15;112(8):3065-72
pubmed: 18650451
N Engl J Med. 2015 Jan 29;372(5):426-35
pubmed: 25629741
Eur J Haematol. 1998 May;60(5):273-7
pubmed: 9654155
N Engl J Med. 2005 Jul 7;353(1):33-45
pubmed: 16000354
Blood. 2009 May 14;113(20):4829-33
pubmed: 19278953
Eur J Haematol. 2019 Aug;103(2):116-123
pubmed: 31107982
Blut. 1990 Jan;60(1):37-40
pubmed: 2105111
Am J Hematol. 2015 Apr;90(4):288-94
pubmed: 25545244
Blood. 2013 Jun 6;121(23):4778-81
pubmed: 23591792
Blood. 2020 May 7;135(19):1696-1703
pubmed: 32107559
Blood. 2015 Dec 10;126(24):2585-91
pubmed: 26486786
Leukemia. 1998 Mar;12(3):289-94
pubmed: 9529121
Leuk Res. 2017 Mar;54:73-77
pubmed: 28113109
Leukemia. 2015 Jan;29(1):20-6
pubmed: 25151955
J Clin Oncol. 2005 Apr 1;23(10):2224-32
pubmed: 15710945
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
N Engl J Med. 2013 Jan 3;368(1):22-33
pubmed: 23216616
Ann Hematol. 1992 May;64(5):207-9
pubmed: 1623054
Ann Hematol. 1991 Oct;63(4):206-9
pubmed: 1932299
Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):417-21
pubmed: 16810617
Eur J Haematol. 1996 Jan-Feb;56(1-2):104-5
pubmed: 8599982
Blood. 2009 Jul 23;114(4):759-63
pubmed: 19372254
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e712-e723
pubmed: 32669244
Eur J Haematol. 1992 Jan;48(1):33-6
pubmed: 1730277
Leuk Res. 2013 Sep;37(9):1041-5
pubmed: 23827351
Cancer. 2005 Jun 15;103(12):2551-7
pubmed: 15861412
Acta Haematol. 1998;99(2):89-91
pubmed: 9554456
Haematologica. 2012 Oct;97(10):1570-3
pubmed: 22419578
Lancet Haematol. 2020 Mar;7(3):e196-e208
pubmed: 32014125
Cancer. 2007 Nov 1;110(9):2012-8
pubmed: 17849460
N Engl J Med. 2017 Jun 1;376(22):2168-2181
pubmed: 28564565
Br J Haematol. 1991 Oct;79 Suppl 1:42-7
pubmed: 1931708
Leuk Lymphoma. 1990;3(2):103-7
pubmed: 27457295
Leuk Res. 2017 Jul;58:63-72
pubmed: 28460339
Leuk Lymphoma. 1991;4(5-6):351-4
pubmed: 27467667
Blood. 1998 Jan 15;91(2):616-22
pubmed: 9427717
Br J Haematol. 1996 Jan;92(1):55-9
pubmed: 8562411
Blood. 2006 Apr 15;107(8):3339-41
pubmed: 16352805
Am J Hematol. 1996 May;52(1):42-6
pubmed: 8638610
Haematologica. 2012 Apr;97(4):538-42
pubmed: 22102708
Haematologica. 2019 Dec;104(12):2391-2399
pubmed: 31123026
J Clin Oncol. 1990 Mar;8(3):556-62
pubmed: 2307991
Haematologica. 2005 Oct;90(10):1333-8
pubmed: 16219569
Hematology. 2009 Dec;14(6):331-4
pubmed: 19941739
Cancer. 2003 Jul 1;98(1):100-9
pubmed: 12833462
Leuk Res. 2014 Oct;38(10):1177-83
pubmed: 25069759
Br J Haematol. 1989 Jun;72(2):173-7
pubmed: 2757963
Tumori. 1995 Jul-Aug;81(4):245-8
pubmed: 8540120

Auteurs

Jan Philipp Bewersdorf (JP)

Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA.

Smith Giri (S)

Division of Hematology and Oncology, University of Alabama School of Medicine, Birmingham, AL, USA.

Rong Wang (R)

Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA.
Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, CT, USA.

Nikolai Podoltsev (N)

Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA.
Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA.

Robert T Williams (RT)

Rockefeller University, New York, NY, USA.

Martin S Tallman (MS)

Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Raajit K Rampal (RK)

Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Amer M Zeidan (AM)

Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA.
Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA.

Maximilian Stahl (M)

Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. stahlm@mskcc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH